- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04875871
Particle-based Partial Tumor Irradiation of Unresectable Bulky Tumors (PARTICLE-PATHY)
Particle-based Partial Tumor Irradiation Targeting Hypoxic Segment and Sparing the Peritumoral Immune Microenvironment for Unresectable Bulky Tumors
Study Overview
Status
Conditions
Intervention / Treatment
- Radiation: Particle radiotherapy
- Diagnostic test: Magnetic resonance imaging
- Diagnostic test: Computertomography
- Diagnostic test: Copper-64-Diacetyl-bis (N4-methylthiosemicarbazone) Positron Emission Tomography-Computer Tomography (64Cu-ATSM-PET-CT)
- Diagnostic test: 18-F-FluorDesoxyGlukose Positron Emission Tomography-Computer Tomography (18F-FDG-PET-CT)
- Diagnostic test: Blood sampling
Detailed Description
This is a mono-centric, prospective, two-arms, feasibility study in which the investigator will enroll up to 22 patients with locally advanced or metastatic cancers with at least one bulky (≥6cm) lesion. This study uses a novel, recently developed unconventional radiotherapy technique, consisting of a short course (3 fractions) high dose partial irradiation targeting exclusively the hypoxic segment of unresectable bulky tumors while sparing the peritumoral immune microenvironment for induction of immune-mediated tumoricidal bystander and abscopal effects.
The present study will explore the potential biological and physical advantages of particle-based radiotherapy to deliver a highly conformal radiation dose to the hypoxic tumor segment defined by using hypoxia-specific Copper-64-Diacetyl-bis (N4-methylthiosemicarbazone) Positron Emission Tomography-Computer Tomography (64Cu-ATSM PET-CT) and dynamic contrast enhanced Magnetic Resonance Tomography imaging. Based on tumor location, volume and risk factors related to nearby organs at risk, patients will be divided in the "high-dose" or "reduced-dose" group which will be treated with different dose-schedules according to risk factors.
Additionally, radiotherapy will be administered at the precise timing, determined individually for each patient, based on the serially mapped homeostatic immune fluctuations by monitoring blood levels of the inflammatory markers. The objective is to synchronize the radiation treatment with the favorable, most reactive anti-tumor immune response phase, in order to break tumor´s immune-tolerance locally and systemically.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Slavisa Tubin, M.D.
- Phone Number: 401 +43 2622 26 100
- Email: slavisa.tubin@medaustron.at
Study Contact Backup
- Name: Eugen B. Hug, Univ. Prof.
- Phone Number: 102 +43 2622 26 100
- Email: eugen.hug@medaustron.at
Study Locations
-
-
Niederösterreich
-
Wiener Neustadt, Niederösterreich, Austria, 2700
- Recruiting
- EBG MedAustron GmbH
-
Contact:
- Slavisa Tubin, M.D.
- Phone Number: 401 +43 2622 26 100
- Email: slavisa.tubin@medaustron.at
-
Principal Investigator:
- Slavisa Tubin, M.D.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Written informed consent obtained from the patient prior to performing any treatment-related procedures.
- Biopsy proven malignant unresectable solid bulky primary or recurrent tumor (diameter of at least 6 cm or greater, except for the Central Nervous System (CNS) tumors), or in a case of lack of recent biopsy progression on at least two consecutive radiological examinations, with biopsy proof in the past. Presence of locally advanced (cN+) and/or metastatic disease will be accepted in order to allow for assessment of the abscopal effects.
- Ineligibility for standard treatments including surgery, conventional (whole tumor) radiotherapy and systemic therapy, or being in progression or stable (with no response to systemic treatment) under systemic therapy.
- A minimum time interval from last dose of systemic therapy before radiotherapy of two weeks; Systemic therapy may be resumed 4 weeks following radiotherapy in order to permit assessment of the treatment efficacy.
- Median life expectancy of >2 months.
- Age > 18 years.
- Adequate bone marrow function as follows below: Haemoglobin ≥ 8.0 g/d; Absolute neutrophil count (ANC) ≥ 1.5 x 10ꝰ/L (> 1500 per mm3); Platelet count ≥ 100 x 10ꝰ/L (>100,000 per mm3).
- Female patients must either be of non-reproductive potential (i.e. post-menopausal by history: ≥60 years old and no menses for ≥1 year without an alternative medical cause; OR history of hysterectomy, OR history of bilateral tubal ligation, OR history of bilateral oophorectomy) OR women of fertile age must have adequate conception prevention measures and must have a negative serum pregnancy test upon study entry.
- Patient is willing and able to comply with the follow up including scheduled visits and examinations.
Exclusion Criteria:
- Patients without bulky lesions.
- Tumors suitable for the standard therapies including surgery, conventional (whole tumor) irradiation and systemic therapies.
- Median life expectancy of less than 2 months.
- Contraindication to i.v. Computer Tomography and Magnetic Resonance Tomography contrast medium administration, particularly estimated glomerular filtration rate (GFR) less than 45 mL/min/1.73 m2.
- History of autoimmune disease.
- Current or prior use of immunosuppressive medication within 14 days before enrollment with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroid.
- History of primary immunodeficiency.
- History of allogeneic organ transplant.
- Uncontrolled intercurrent comorbidity including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, active bleeding diatheses including any patient known to have evidence of acute or chronic hepatitis B, hepatitis C or human immunodeficiency virus (HIV), or psychiatric illness/social situations that would limit compliance with study requirements or compromise the ability of the patient to give written informed consent.
- Female patients who are pregnant, breast-feeding or male or female patients of reproductive potential who are not employing an effective method of birth control.
- Any condition that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results. (Note: criterion will be evaluated on the four eyes principle, evaluated by both Principle Investigator and Sub-Investigators.)
- Patients with uncontrolled seizures.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: High-dose group
3 fractions of 12 Gy Relative Biological Effectiveness (RBE)
|
Partial radiotherapy targeting the hypoxic tumor segment
For treatment planning as well as for follow-up radiological tumor assessment.
For treatment planning as well as for follow-up radiological tumor assessment.
For the definition of the hypoxic tumor segment in treatment planning.
For follow-up radiological tumor assessment.
Evaluation before treatment-start, during treatment and follow-up period.
|
Experimental: Reduced-dose group
3 fractions of 8-10 Gy RBE
|
Partial radiotherapy targeting the hypoxic tumor segment
For treatment planning as well as for follow-up radiological tumor assessment.
For treatment planning as well as for follow-up radiological tumor assessment.
For the definition of the hypoxic tumor segment in treatment planning.
For follow-up radiological tumor assessment.
Evaluation before treatment-start, during treatment and follow-up period.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Bystander (local) tumor response rate
Time Frame: 11 months (after treatment)
|
Bystander (local, at the level of the partially treated bulky tumor) response rate defined as at least a 30% regression of the unirradiated tumor tissue.
|
11 months (after treatment)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Feasibility of PARTICLE-PATHY
Time Frame: 3,5 years (recruiting time + treatment time + 11 months follow-up)
|
Feasibility of patient recruitment, treatment and follow-up rates.
|
3,5 years (recruiting time + treatment time + 11 months follow-up)
|
Overall survival
Time Frame: 11 months (after treatment)
|
Defined as the time from treatment until the time of death from any cause.
|
11 months (after treatment)
|
Time to local tumor progression
Time Frame: 11 months (after treatment)
|
Defined as the time from treatment until the time of local disease progression.
|
11 months (after treatment)
|
Time to distant tumor progression
Time Frame: 11 months (after treatment)
|
Defined as the time from treatment until the time of distant disease progression.
|
11 months (after treatment)
|
Abscopal (distant) tumor response rate
Time Frame: 11 months (after treatment)
|
Defined as the proportion of metastatic patients that exhibited an abscopal effect versus the total number of metastatic patients allocated to the treatment.
|
11 months (after treatment)
|
Symptoms relief
Time Frame: 11 months (after treatment)
|
Proportion of patients who will achieve a partial or complete relief at different time-points.
|
11 months (after treatment)
|
Radiation related toxicity
Time Frame: 11 months (after treatment)
|
Toxicity assessment according to NCI CTCAE v5.0
|
11 months (after treatment)
|
Feasibility of timing of PARTICLE-PATHY and its relation to clinical outcomes
Time Frame: Until 11 months after treatment
|
The feasibility of PARTICLE-PATHY and to it related TIMING will be defined by the proportion of patients allocated to this treatment who received it within dosimetric constraints after being able to define the immune-cycle periodicity and to synchronize radiotherapy with it versus the total number of patients allocated to the treatment.
|
Until 11 months after treatment
|
Bystander/abscopal response rate in relation to dose-size of Peritumoral Immune Microenvironment (PIM)
Time Frame: 11 months (after treatment)
|
See title
|
11 months (after treatment)
|
Bystander/abscopal response rate in relation to Interleukin-2 and Interferon Gamma values
Time Frame: 11 months (after treatment)
|
Two key cytokines, Interleukin-2 (IL-2) and Interferon Gamma (INFg), will be serially assessed at baseline and after each radiotherapy treatment, in order to determine their potential role in modulating the immune response in relation to the bystander/abscopal effects.
|
11 months (after treatment)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Slavisa Tubin, M.D., EBG MedAustron
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PATHY-MA-072020
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
University of Michigan Rogel Cancer CenterRecruitingCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
UNC Lineberger Comprehensive Cancer CenterHyundai Hope On WheelsRecruitingCancer | Pediatric Cancer | Survivorship | Cancer MetastaticUnited States
-
MiRXES Pte LtdRecruitingBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Thoracic Cancer | Liver CancerSingapore
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedGastric Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Colon Cancer | Hepatobiliary CancerUnited States
-
Johns Hopkins UniversityNational Cancer Institute (NCI); National Institute on Minority Health and...Enrolling by invitationCancer | Advanced Cancer | End Stage Cancer | MalignancyUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IV Gastric Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic Cancer | Stage IVB Colorectal Cancer | Stage IVB Pancreatic Cancer | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric... and other conditionsUnited States
-
Case Comprehensive Cancer CenterCompletedStage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Stage IVA Colon Cancer | Stage IVA Rectal Cancer and other conditionsUnited States
Clinical Trials on Particle radiotherapy
-
University Hospital HeidelbergDietmar Hopp StiftungCompleted
-
University of UtahCompleted
-
University of Alabama at BirminghamCompletedAlveolar Ridge Preservation | Alveolar Ridge AugmentationUnited States
-
Chinese University of Hong KongUnknownTo See if Colonoscopy is an Aerosol-generating Procedure and to Identify Ways to Minimise the Aerosol GeneratedHong Kong
-
Hasselt UniversityZiekenhuis Oost-LimburgRecruiting
-
Nanospectra Biosciences, Inc.Active, not recruitingNeoplasms of the ProstateUnited States
-
Nanospectra Biosciences, Inc.CompletedNeoplasms of the ProstateUnited States
-
Konstantinos SiontisActive, not recruiting
-
Eli Lilly and CompanyCompleted
-
Massachusetts General HospitalCompletedChondrosarcoma | ChordomaUnited States